Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis

No authors listed

Published Erratum

No authors listed. Neurol Neuroimmunol Neuroinflamm. 2023.

. 2023 Mar 27;10(3):e200120.

doi: 10.1212/NXI.0000000000200120. Print 2023 May.

No abstract available

Erratum for

Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.
Hauser SL, Bar-Or A, Weber MS, Kletzl H, Günther A, Manfrini M, Model F, Mercier F, Petry C, Wing Q, Koendgen H, Smith T, Kappos L. Hauser SL, et al. Neurol Neuroimmunol Neuroinflamm. 2023 Feb 15;10(2):e200094. doi: 10.1212/NXI.0000000000200094. Print 2023 Mar. Neurol Neuroimmunol Neuroinflamm. 2023. PMID: 36792367 Free PMC article. Clinical Trial.

1. Hauser SL, Bar-Or A, Weber MS, et al. Association of higher ocrelizumab exposure with reduced disability progression in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2023;10(2):e200094. - PMC - PubMed